"US President Donald Trump held a press conference on Thursday to announce a groundbreaking deal with pharmaceutical giants Eli Lilly and Novo Nordisk to lower the prices of weight-loss drugs. Trump scored the concessions with the two pharma giants in exchange for providing them relief from US tariffs. The move is the latest attempt by the Trump administration to tackle soaring drug prices in the US."
"The drugs produced by Eli Lilly and Novo Nordisk, known as GLP-1s, target hormones in the gut and brain that regulate appetite and feelings of fullness. Patients new to the drug will generally start with smaller doses and then build up to larger doses, depending on the patient's need. But experts say patients need to stay on the drug indefinitely or risk regaining weight."
"The drug brands Ozempic, Wegovy and Mounjaro have risen sharply in popularity in the US. Despite that popularity, they are considered unaffordable, as they can cost more than $1,000 (866) per month. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video How much cheaper will the drugs be? Trump said his plan would lower the costs of products for those eligible."
President Donald Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices of GLP-1 weight-loss drugs in exchange for relief from US tariffs. Pfizer and AstraZeneca previously agreed to lower prescription costs for Medicaid after an executive order that set a deadline for drugmakers to reduce prices or face new limits on government payments. Eli Lilly and Novo Nordisk committed to offer Zepbound and Wegovy at 'Most Favored Nation' rates for American patients and to provide drastic discounts. GLP-1 drugs target gut and brain hormones, often require ongoing use, and can cost over $1,000 per month.
Read at www.dw.com
Unable to calculate read time
Collection
[
|
...
]